奥泰生物(688606) - 2023 Q1 - 季度财报

Financial Performance - The company's operating revenue for Q1 2023 was CNY 236,135,335.17, representing a decrease of 88.75% compared to the same period last year[4] - The net profit attributable to shareholders for Q1 2023 was CNY 40,532,500.99, down 96.14% year-over-year[4] - Basic earnings per share for Q1 2023 were CNY 0.75, a decrease of 96.15% from the same quarter last year[4] - Total operating revenue for Q1 2023 was CNY 236,135,335.17, a decrease from CNY 2,098,917,066.48 in Q1 2022[16] - Net profit for Q1 2023 was CNY 40,336,129.33, significantly lower than CNY 1,049,121,215.40 in Q1 2022[18] - Earnings per share for Q1 2023 was CNY 0.75, compared to CNY 19.46 in Q1 2022[18] - The company reported a profit before tax of CNY 46,055,548.68 for Q1 2023, down from CNY 1,236,948,635.58 in Q1 2022[18] - The company experienced a significant reduction in sales expenses, which were CNY 16,674,929.87 in Q1 2023 compared to CNY 42,667,201.09 in Q1 2022[16] - The company reported a decrease in other income to CNY 576,469.16 in Q1 2023 from CNY 3,968,247.34 in Q1 2022[16] Cash Flow - The net cash flow from operating activities was negative CNY 177,675,720.76, reflecting a decline of 119.07% compared to the previous year[4] - Cash inflow from operating activities totaled CNY 178,230,168.16, a decrease of 91.3% compared to CNY 2,051,952,557.39 in Q1 2022[19] - Cash outflow from operating activities was CNY 355,905,888.92, down from CNY 1,120,078,405.87 in the same period last year[20] - The cash flow from operating activities showed a net outflow of CNY 162,215,506.83 in Q1 2023, compared to a net inflow of CNY 558,267,927.44 in Q1 2022[28] - Cash and cash equivalents amounted to ¥1,898,544,294.47, down from ¥1,981,842,773.82, indicating a decrease of about 4.2%[12] - Total cash and cash equivalents at the end of Q1 2023 amounted to CNY 1,869,528,440.30, down from CNY 3,057,332,086.11 at the end of Q1 2022[20] - The ending balance of cash and cash equivalents is approximately $1.46 billion, compared to $2.64 billion in the previous period[29] Assets and Liabilities - Total assets at the end of the reporting period were CNY 4,568,155,740.18, down 2.80% from the end of the previous year[5] - The company's total current assets decreased to ¥3,948,084,209.49 from ¥4,189,174,367.17, reflecting a reduction of approximately 5.8%[13] - The total liabilities decreased to CNY 350,496,292.76 in Q1 2023 from CNY 528,800,790.03 in Q1 2022[15] - The total liabilities decreased to CNY 229,573,157.02 in Q1 2023 from CNY 431,701,653.17 in Q1 2022, reflecting a reduction of approximately 46.7%[24] - The company's non-current assets totaled ¥620,071,530.69, up from ¥510,548,813.65, marking an increase of approximately 21.5%[13] - Current assets decreased to CNY 3,653,877,542.39 from CNY 3,853,352,649.30 year-over-year[23] Research and Development - Research and development expenses totaled CNY 36,121,641.21, which is a decrease of 22.89% year-over-year, but accounted for 15.30% of operating revenue, an increase of 13.07 percentage points[5] - Research and development expenses for Q1 2023 were CNY 36,121,641.21, down from CNY 46,841,374.33 in Q1 2022[16] - Research and development expenses for Q1 2023 were CNY 33,550,901.15, down from CNY 42,967,221.89 in Q1 2022, a decrease of about 21.8%[26] Shareholder Information - The top 10 shareholders collectively control 52.42% of the company’s shares, with the largest shareholder holding 23.18%[10] - The company repurchased 1,036,000 shares, representing 1.9219% of total shares, which is not included in the top 10 shareholders list[10] Other Financial Information - The company reported a non-operating income of CNY 11,656,585.11, after accounting for tax effects[6] - The company has not conducted an audit for the Q1 financial statements[4] - The company has adopted new accounting standards starting in 2023, which may affect the financial statements[29] - The report indicates that there are no adjustments made to the financial statements for the first execution year of the new accounting standards[29] - The financial report is presented by the company’s responsible person, Gao Fei, and the accounting work is overseen by Fu Yanping[29] - The report does not specify any new product developments or market expansion strategies[29] - There is no mention of mergers or acquisitions in the current financial report[29] - Future outlook and performance guidance are not detailed in the provided content[29]